Chi-Fai, Anthony Ng

Prof. Chi-Fai, Anthony Ng

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in European Urology
Verified
Journal Article
Open access
Martin WongMartin Wong
Martin Wong
WGWilliam B. Goggins
William B. Goggins
Harry H.X. WangHarry H.X. Wang
Harry H.X. Wang
FFFranklin D.H. Fung
Franklin D.H. Fung
CLColette Leung
Colette Leung
JSJoseph JY Sung
Joseph JY Sung
Prostate cancer (PCa) is a leading cause of mortality and morbidity globally, but its specific geographic patterns and temporal trends are under-researched. To test the hypotheses that PCa incidence is higher and PCa mortality is lower in countries with higher socioeconomic development, and that temporal trends for PCa incidence have increased while mortality has decreased over time. Data on age-standardized incidence and mortality rates in 2012 were retrieved from the GLOBOCAN database. Temporal patterns were assessed for 36 countries using data obtained from Cancer incidence in five continents volumes I-X and the World Health Organization mortality database. Correlations between incidence or mortality rates and socioeconomic indicators (human development index [HDI] and gross domestic product [GDP]) were evaluated. The average annual percent change in PCa incidence and mortality in the most recent 10 yr according to join-point regression. Reported PCa incidence rates varied more than 25-fold worldwide in 2012, with the highest incidence rates observed in Micronesia/Polynesia, the USA, and European countries. Mortality rates paralleled the incidence rates except for Africa, where PCa mortality rates were the highest. Countries with higher HDI (r=0.58) and per capita GDP (r=0.62) reported greater incidence rates. According to the most recent 10-yr temporal data available, most countries experienced increases in incidence, with sharp rises in incidence rates in Asia and Northern and Western Europe. A substantial reduction in mortality rates was reported in most countries, except in some Asian countries and Eastern Europe, where mortality increased. Data in regional registries could be underestimated. PCa incidence has increased while PCa mortality has decreased in most countries. The reported incidence was higher in countries with higher socioeconomic development. The incidence of prostate cancer has shown high variations geographically and over time, with smaller variations in mortality.

18 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Martin WongMartin Wong
Martin Wong
FFFranklin D. H. Fung
Franklin D. H. Fung
CLColette Leung
Colette Leung
WCWilson W. L. Cheung
Wilson W. L. Cheung
WGWilliam B. Goggins
William B. Goggins
CNChi-Fai, Anthony Ng
Chi-Fai, Anthony Ng
We tested the hypotheses that the global incidence of bladder cancer was increasing but its mortality was reducing and its incidence was positively correlated with country-specific socioeconomic development. We retrieved data on age-standardized incidence and mortality rates/100,000 from the GLOBOCAN database in 2012. Temporal patterns were examined for 39 countries from the Cancer Incidence in Five Continents volumes I-X and other national registries. We evaluated the correlation between the incidence/mortality rates and Human Development Index (HDI)/ logarithmic values of Gross Domestic Product per capita (GDP). The average annual percent change of the incidence and mortality rates in the most recent 10 years was examined by joinpoint regression analysis. The highest incidence rates were observed in Southern Europe, Western Europe and North America. The mortality rates were the highest in Western Asia and Northern Africa. The incidence was positively correlated with HDI (r = 0.66 [men]; r = 0.50 [women]) and to a lesser extent logarithmic values of GDP per capita (r = 0.60 [men]; r = 0.50 [women], all p < 0.01). Many European countries experienced incidence rise. A substantial mortality reduction was observed in most countries, yet increases in mortality rates were observed in the Philippines and Iceland. These findings identified countries where more preventive actions are required.

5 March 2010 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
QCQ K Y Chan
Q K Y Chan
HLH-M Lam
H-M Lam
CNChi-Fai, Anthony Ng
Chi-Fai, Anthony Ng
ALA Y Y Lee
A Y Y Lee
ECE S Y Chan
E S Y Chan
KLKin-Mang Lau
Kin-Mang Lau
G-protein-coupled receptor-30 (GPR30) shows estrogen-binding affinity and mediates non-genomic signaling of estrogen to regulate cell growth. We here showed for the first time, in contrast to the reported promoting action of GPR30 on the growth of breast and ovarian cancer cells, that activation of GPR30 by the receptor-specific, non-estrogenic ligand G-1 inhibited the growth of androgen-dependent and androgen-independent prostate cancer (PCa) cells in vitro and PC-3 xenografts in vivo. However, G-1 elicited no growth or histological changes in the prostates of intact mice and did not inhibit growth in quiescent BPH-1, an immortalized benign prostatic epithelial cell line. Treatment of PC-3 cells with G-1 induced cell-cycle arrest at the G2 phase and reduced the expression of G2-checkpoint regulators (cyclin-A2, cyclin-B1, cdc25c, and cdc2) and phosphorylation of their common transcriptional regulator NF-YA in PC-3 cells. With extensive use of siRNA-knockdown experiments and the MEK inhibitor PD98059 in this study, we dissected the mechanism underlying G-1-induced inhibition of PC-3 cell growth, which was mediated through GPR30, followed by sustained activation of Erk1/2 and a c-jun/c-fos-dependent upregulation of p21, resulting in the arrest of PC-3 growth at the G2 phase. The discovery of this signaling pathway lays the foundation for future development of GPR30-based therapies for PCa.

28 October 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JGJulius Gudmundsson
Julius Gudmundsson
PSPatrick Sulem
Patrick Sulem
DGDaniel F Gudbjartsson
Daniel F Gudbjartsson
GMGisli Masson
Gisli Masson
BABjarni A Agnarsson
Bjarni A Agnarsson
KSKari Stefansson
Kari Stefansson

1 September 2012 in Hypertension
Verified
Journal Article
Closed access
LLLimei Liu
Limei Liu
JLJian Liu
Jian Liu
Wing Tak WongWing Tak Wong
Wing Tak Wong
XTXiao Yu Tian
Xiao Yu Tian
CLChi Wai Lau
Chi Wai Lau
Yu HuangYu Huang
Yu Huang
Sitagliptin, a selective dipeptidyl peptidase 4 inhibitor, inhibits the inactivation and degradation of glucagon like peptide 1 (GLP-1), which is used for the treatment of type 2 diabetes mellitus. However, little is known about the role of GLP-1 in hypertension. This study investigated whether the activation of GLP-1 signaling protects endothelial function in hypertension. Two-week sitagliptin treatment (10 mg/kg per day, oral gavage) improved endothelium-dependent relaxation in renal arteries, restored renal blood flow, and reduced systolic blood pressure in spontaneously hypertensive rats. In vivo sitagliptin treatment elevated GLP-1 and GLP-1 receptor expressions, increased cAMP level, and subsequently activated protein kinase A, liver kinase B1, AMP-activated protein kinase-α and endothelial NO synthase in spontaneously hypertensive rat renal arteries. Inhibition of GLP-1 receptor, adenylyl cyclase, protein kinase A, AMP-activated protein kinase-α, or NO synthase reversed the protective effects of sitagliptin. We also demonstrate that GLP-1 receptor agonist exendin 4 in vitro treatment had similar vasoprotective effects in spontaneously hypertensive rat renal arteries and increased NO production in spontaneously hypertensive rat aortic endothelial cells. Studies using transient expressions of wild-type and dominant-negative AMP-activated protein kinase-α2 support the critical role of AMP-activated protein kinase-α in mediating the effect of GLP-1 in endothelial cells. Ex vivo exendin 4 treatment also improved endothelial function of renal arteries from hypertensive patients. Our results elucidate that upregulation of GLP-1 and related agents improve endothelial function in hypertension by restoring NO bioavailability, suggesting that GLP-1 signaling could be a therapeutic target in hypertension-related vascular events.

11 August 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Patrick Ming Kuen TangPatrick Ming Kuen Tang
Patrick Ming Kuen Tang
YZYing-Ying Zhang
Ying-Ying Zhang
JXJun Xiao
Jun Xiao
PTPhilip Chiu-Tsun Tang
Philip Chiu-Tsun Tang
JCJeff Yat-Fai Chung
Jeff Yat-Fai Chung
HLHui-yao Lan
Hui-yao Lan
Significance: Macrophage–myofibroblast transition (MMT) is a newly discovered pathogenic process by which TGF-β1/Smad3 signaling promotes tissue scarring. However, systemic targeting of Smad3 may impair host T cell immunity; therefore, it is preferable to focus on downstream mechanisms to identify antifibrotic therapies that avoid targeting Smad3 per se. In this study, we revealed a brain-specific transcription factor Pou4f1 as the key regulator by which TGF-β1/Smad3 signaling executes MMT. Macrophage-specific silencing of Pou4f1 effectively blocked progression of renal fibrosis in two mouse kidney disease models. Thus, Pou4f1 represents a therapeutic target in MMT-driven renal diseases.